Presentation and outcomes of KRASG12C mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence
Niki Esfahanian(University Health Network), Geoffrey Liu(Princess Margaret Cancer Centre), Natasha B. Leighl(Princess Margaret Cancer Centre), Khaleeq Khan(Princess Margaret Cancer Centre), Jennifer J. Parker(University Health Network), M. Catherine Brown(University Health Network), Adrian G. Sacher(Princess Margaret Cancer Centre), Stephanie Snow(Dalhousie University), Elizabeth Yan(Juravinski Cancer Centre), Lawson Eng(Princess Margaret Cancer Centre), Luna Jia Zhan(University Health Network), Frances A. Shepherd(University Health Network), Jae Lee(University Health Network), Sze Wah Samuel Chan(Juravinski Cancer Centre), Samir H. Barghout, Karmugi Balaratnam(Princess Margaret Cancer Centre), Miguel García-Pardo(Hospital Universitario Ramón y Cajal), Penelope A. Bradbury(University Health Network), Rosalyn A. Juergens(McMaster University)
Cited by 2
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
|The Lancet|2014|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k